Stifel Nicolaus Boosts uniQure (NASDAQ:QURE) Price Target to $32.00

uniQure (NASDAQ:QURE) had its price objective hoisted by Stifel Nicolaus from $12.00 to $32.00 in a report released on Monday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

Several other research firms also recently weighed in on QURE. Leerink Partners upped their price target on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of uniQure in a research note on Tuesday, December 10th. Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and lifted their price target for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. Guggenheim reissued a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Finally, Wells Fargo & Company upgraded shares of uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.13.

uniQure Stock Up 13.0 %

NASDAQ:QURE opened at $17.40 on Monday. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The firm’s 50-day moving average price is $7.04 and its 200-day moving average price is $6.38. The company has a market capitalization of $848.13 million, a PE ratio of -3.36 and a beta of 0.89. uniQure has a 1-year low of $3.73 and a 1-year high of $17.71.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. On average, equities analysts predict that uniQure will post -3.82 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This represents a 0.57 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.74% of the stock is owned by insiders.

Institutional Trading of uniQure

Several large investors have recently modified their holdings of the company. abrdn plc grew its position in uniQure by 381.7% during the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after buying an additional 1,528,581 shares during the period. Franklin Resources Inc. purchased a new position in shares of uniQure during the 3rd quarter worth $7,360,000. Point72 Asset Management L.P. grew its position in shares of uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after acquiring an additional 752,889 shares during the period. FMR LLC increased its stake in shares of uniQure by 8,056.6% in the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after purchasing an additional 346,274 shares in the last quarter. Finally, Assenagon Asset Management S.A. bought a new position in uniQure in the 2nd quarter worth $815,000. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.